Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Scott Moomaw sold 80,000 shares of common stock for a transaction value of approximately ~$2.83 million on March 9, 2026. The transaction represented 29.74% of his direct holdings, reducing direct ownership to 188,954 shares after the sale.

The chief medical officer of Liquidia sold 35,365 common shares on March 13, 2026, for a transaction value of $1.28 million at around $36.30 per share. The sale was executed entirely from direct holdings; no indirect or derivative securities were involved.

Low-beta picks gain focus as Iran war fears stir volatility. AGRO, PRA, E and LQDA reflect resilience with momentum, liquidity and fundamentals.

Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Liquidia Corporation (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.

STRL, LQDA and NWPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 10th, 2026.